Zydus Lifesciences Limited
ZYDUSLIFE
Helyezés a részvények között
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Részvényárfolyam
$12.30
Piaci kapitalizáció
$12.27B
Változás (1 nap)
0.06%
Változás (1 év)
8.33%
Ország
IN
Kereskedés Zydus Lifesciences Limited (ZYDUSLIFE)
Kategória
Healthcare
EPS Zydus Lifesciences Limited (ZYDUSLIFE) részvényre
EPS June 2026 dátummal, TTM: $0.50
Zydus Lifesciences Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $0.50. 2024 végén a vállalat EPS mutatója $0.45 volt, növekedés a 2023 év EPS értékéhez, amely $0.24 volt.
Zydus Lifesciences Limited EPS története 2004 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $0.50 | -6.57% |
| 2025 | $0.53 | 15.66% |
| 2024 | $0.45 | 93.04% |
| 2023 | $0.24 | -18.37% |
| 2022 | $0.29 | -1.80% |
| 2021 | $0.29 | 92.66% |
| 2020 | $0.15 | -41.37% |
| 2019 | $0.26 | -3.38% |
| 2018 | $0.27 | 19.91% |
| 2017 | $0.22 | -21.26% |
| 2016 | $0.29 | 58.30% |
| 2015 | $0.18 | 37.48% |
| 2014 | $0.13 | 11.58% |
| 2013 | $0.12 | -6.53% |
| 2012 | $0.13 | -19.49% |
| 2011 | $0.16 | 112.82% |
| 2010 | $0.07 | 16.35% |
| 2009 | $0.06 | -7.62% |
| 2008 | $0.07 | 19.23% |
| 2007 | $0.06 | -98.42% |
| 2006 | $3.63 | 6,117.81% |
| 2005 | $0.06 | -10.43% |
| 2004 | $0.07 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 12.34% |
IN
|
